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Dermatitis herpetiformis arising within vitiligo in a
patient with autoimmune polyendocrine syndrome type 3
The association between dermatitis herpetiformis (DH) and viti-
ligo is infrequent. It concerns 1.3% of the patients with DH1 and
1% of the patients with vitiligo.2 Case reports showed a peculiar
affinity of DH lesions for vitiligo patches.3–9 We report here an
illustrative case of DH that displayed affinity phenomenon on
vitiligo patches in a patient with autoimmune polyendocrine syn-
drome (APS) type 3.
A 47-year-old woman presented with a 2-week history of pru-
ritic papulovesicular rash. Her past medical history included
type 1 diabetes, hypothyroidism, vitiligo, asthma, hypertension,
atopic eczema, and mood disorder. Her two children had celiac
disease. The patient had a previous blood screening test with
positive tissue transglutaminase IgA antibodies (19; normal <7).
She denied any intestinal symptoms, and past gastroscopy and
biopsies of the duodenum were normal. She had been followed
in the past in our clinic for an itchy rash. Despite recurrent sus-
picions of DH, direct immunofluorescence (DIF) remained nega-
tive on several occasions 20 years ago. The rash had been
treated since as atopic eczema with topical corticosteroids and
moisturizers. Upon examination, the patient had symmetrical
pruritic erythematous papules, vesicles, and excoriations on
extensor surfaces of elbows, knees, and buttocks. She also dis-
played lesions on wrists, ankles, pubic area, and hairline
(Fig. 1). The lesions were mainly localized within vitiligo. Vitiligo
patches on the inner thighs and abdomen were mainly spared.
DH disease was again highly suspected. A punch skin biopsy of
a vesicle showed upper dermal inflammation with lymphocytes,
macrophages and eosinophils, and subepidermal, cleavage.
Two DIF from an erythematous area and a normal appearing
perilesional area revealed granular IgA deposition on the basal
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Figure 1 Vesicules of DH restricted to vitiligo of the elbows and forearm (a), knees (b), and dorsum of the hand (c).
Complete regression after 3 months with dapsone 100 mg/day and gluten-free diet (d)
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membrane. She started oral disulone 100 mg/day along with
gluten-free diet. No gastroscopy was performed. At 3-month
follow-up, the patient was clear of any lesion.
We report here a new case of association between DH and
vitiligo. Our case is striking by the very strong autoimmune per-
sonal and familial context. The patient had APS type 3, which is
defined by autoimmune thyroiditis with other organ-specific
immunity, here type 1 diabetes and vitiligo, but without adrenal
insufficiency.10 A previous case was reported with APS type 2.9
The localization and affinity of DH lesions within vitiligo is strik-
ing. We found 12 other cases of DH coexisting with vitiligo in
the literature (Table 1).1–9 Half were women, and the median
age at diagnosis of DH was 36 years. In most of the cases (7/
9), vitiligo preceded DH. DH was co-localized totally or at least
partly on vitiligo in 7/8 patients. Only Allende et al. reported a
case of DH sparing vitiligo patches.3 Additional autoimmune
features were found in 5/8 patients with either APS (2/8), circu-
lating antithyroid antibodies (2/8), or in one case membranous
glomerulonephritis during follow-up.5 The mechanism of DH
affinity for vitiligo patches is unknown. Hypotheses of the litera-
ture include: (i) K€oebner phenomenon,4 (ii) genetic mosaicism
in case of segmental vitiligo,9 (iii) fortuitous as DH lesions may
be located on other areas without vitiligo.8 Besides, DH anti-
gens could be unmasked in vitiliginous areas under the action
of UV exposure, trauma, or modified local immunity associated
with melanocyte destruction.
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Table 1 Reported cases of dermatitis herpetiformis associated with vitiligo
Case Author Gender
Age (years) at the time
of diagnosis of DH Co-localization
First
pathology Other autoimmune conditions
1 Allende et al., 19643 M 35 No Vitiligo No
2 Ortonne et al., 19762 – – – – –
3 Olholm-Larsen et al., 19804 W 33 Yes DH No
4 Combs et al., 19805 M 25 Yes Vitiligo MGN
5 Hogan et al., 19866 W 46 Yes Vitiligo Antithyroid antibodies without
hypothyroidism
6 Reunala et al., 19971 W – – – –
7 Reunala et al., 19971 M – – – –
8 Reunala et al., 19971 M – – – –
9 Reunala et al., 19971 M – – DH –
10 Amato et al., 20007 W 53 Yes Vitiligo Antithyroid antibodies without
hypothyroidism
11 Karabudak et al., 20078 M 21 Yes Vitiligo No
12 Macbeth et al., 20139 W 37 Yes Vitiligo APS-2 (thyroiditis, adrenal insufficiency,
DT1, CD)
13 Present case, 2018 W 47 Yes Vitiligo APS-3 (DT1, thyroiditis, vitiligo)
APS, autoimmune polyendocrine syndrome; CD, celiac disease; DT1, type 1 diabetes; M, man; MGN, membranous glomeru-
lonephritis; NA, not available; W, woman.
a
Cases extracted from large series. No specific clinical data given.
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